Pfizer: ‘Dropped preclinical programs do not change commitment to biosimilarsâ
In the latest example of a Big Biopharma reducing its biosimilar presence, Pfizer has abandoned five of its preclinical programs. The decision is part of an R&D review set to cut 150 jobs in Illinois and India. In November 2018, Bioprocess Insider reported claims that Big Pharma is set to exi ...
Advaxis says Amgen’s withdrawal from a 2016 personalized immuno-oncology partnership is due to portfolio rationalization, high cost of goods, a ...
The FDA has approved Ontruzant, the third version of Roche’s cancer drug Herceptin, and the second US biosimilar approval for Samsung Bioepis. ...
The US Biomedical Advanced Research and Development Authority (BARDA) has exercised a second option in its smallpox vaccine contract with Bavaria ...
It took Eli Lilly 18 days from expressing its interest in Loxo Oncology to executing an $8 billion merger agreement. Being a “significant premi ...
Recent Tweets
-
COGs factor in Amgen’s exit from $540m Advaxis deal https://t.co/eq6PephYpN
4 hours ago
-
RT @Dan5tanton: It took Eli Lilly 18 days from expressing its interest in Loxo Oncology to executing an $8 billion merger agreement… https://t.co/8jdTN4yJSb
4 days ago
-
RT @Dan5tanton: In the latest example of a Big Biopharma reducing its biosimilar presence, Pfizer has abandoned five of its preclin… https://t.co/SZNtQSUaiY
5 days ago
-
RT @Dan5tanton: After raising $324 million last year, @AllogeneTx says it is planning to construct a cell therapy manufacturing fa… https://t.co/a5QS2fiPfZ
7 days ago
